NO20063340L - Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer - Google Patents

Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer

Info

Publication number
NO20063340L
NO20063340L NO20063340A NO20063340A NO20063340L NO 20063340 L NO20063340 L NO 20063340L NO 20063340 A NO20063340 A NO 20063340A NO 20063340 A NO20063340 A NO 20063340A NO 20063340 L NO20063340 L NO 20063340L
Authority
NO
Norway
Prior art keywords
optionally substituted
alkyl
fluoroalkyl
cycloalkyl
formula
Prior art date
Application number
NO20063340A
Other languages
English (en)
Inventor
Martin Redpath Johnson
Michael Dennis Dowle
Alison Judith Redgrave
Paul Spencer Jones
Caroline Mary Cook
Diane Mary Coe
Julie Nicole Hamblin
David George Allen
Christopher David Edlin
Mika Kristian Lindvall
Charlotte Jane Mitchell
John Edward Robinson
Naimisha Trivedi
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/014867 external-priority patent/WO2004056823A1/en
Priority claimed from GB0405936A external-priority patent/GB0405936D0/en
Priority claimed from GB0405899A external-priority patent/GB0405899D0/en
Priority claimed from GB0406754A external-priority patent/GB0406754D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20063340L publication Critical patent/NO20063340L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel (I) eller et salt derav, hvor Ar har underformelen (x) eller (z): og hvor R3 er eventuelt substituert C3-8cykloalkyl, eventuelt substituert C5-7 cykloalkenyl, en eventuelt substituert hete-rocyklisk gruppe (aa), (bb) eller (cc), eller en bicyklisk gruppe (ee); og hvor R4 er H, C1-3alkyl, C1-2fluoralkyl, cyklopropyl, -CH2OR4a, -CH(Me)OR4a eller -CH2CH2OR4a; og R5 er inter alia H, C1-8alkyl, C1-8fluoralkyl, C3.8cykloalkyl, visse substituerte alkylgrupper, -(CH2)n13-Het eller eventuelt substituert fenyl eller -CH2-Ph; eller R4 og R5 tatt sammen er -(CH2)p1- eller -(CH2)P3-X5-(CH2)P4-; forutsatt at minst én av R4 og R5 ikke er et hydrogenatom (H). Oppfinnelsen tilveiebringer også anvendelsen av forbindelsene som inhibitorer av fosfodiesterase type IV (PDE4) og/eller for behandlingen og/eller forebyggingen av inflammatoriske og/eller allergiske sykdommer så som kronisk obstruktiv lungesykdom (KOLS), astma, revmatoid artritt, allergisk rhinitt eller atopisk dermatitt.
NO20063340A 2003-12-19 2006-07-18 Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer NO20063340L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2003/014867 WO2004056823A1 (en) 2002-12-23 2003-12-19 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
GB0405936A GB0405936D0 (en) 2004-03-16 2004-03-16 Compounds
GB0405899A GB0405899D0 (en) 2004-03-16 2004-03-16 Compounds
GB0406754A GB0406754D0 (en) 2004-03-25 2004-03-25 Compounds
PCT/EP2004/014490 WO2005058892A1 (en) 2003-12-19 2004-12-17 Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
NO20063340L true NO20063340L (no) 2006-09-12

Family

ID=37101558

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063340A NO20063340L (no) 2003-12-19 2006-07-18 Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer

Country Status (6)

Country Link
US (2) US20070111995A1 (no)
JP (1) JP2007514704A (no)
AU (1) AU2004299277A1 (no)
CA (1) CA2557004A1 (no)
NO (1) NO20063340L (no)
WO (1) WO2005058892A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
BR0314392A (pt) * 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
CA2557004A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
WO2005090354A1 (en) * 2004-03-16 2005-09-29 Glaxo Group Limited PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
CA2611376C (en) * 2005-06-13 2013-09-10 Merck Sharp & Dohme Limited Therapeutic agents
EP1973905A4 (en) * 2006-01-06 2010-12-08 Astrazeneca Ab COMPOUNDS
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US20090012010A1 (en) * 2007-05-18 2009-01-08 Neuromed Phramaceuticals Ltd. Amino acid derivatives as calcium channel blockers
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
UY31637A1 (es) * 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
SG177306A1 (en) * 2009-07-10 2012-02-28 Taiho Pharmaceutical Co Ltd Azabicyclo compound and salt thereof
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US20120052122A1 (en) * 2010-08-26 2012-03-01 Nycomed Gmbh Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
EA029892B1 (ru) 2012-04-25 2018-05-31 Такеда Фармасьютикал Компани Лимитед Азотсодержащее гетероциклическое соединение
JP6205356B2 (ja) 2012-07-13 2017-09-27 武田薬品工業株式会社 複素環化合物
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC CONNECTION
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
US20160264536A1 (en) * 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2022053931A1 (en) 2020-09-08 2022-03-17 Galderma Holding SA Novel jak inhibitor compounds, method for synthesizing same and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) * 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
BR0314392A (pt) * 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CA2557004A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
WO2005090354A1 (en) * 2004-03-16 2005-09-29 Glaxo Group Limited PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

Also Published As

Publication number Publication date
JP2007514704A (ja) 2007-06-07
US20080132536A1 (en) 2008-06-05
US20070111995A1 (en) 2007-05-17
AU2004299277A1 (en) 2005-06-30
CA2557004A1 (en) 2005-06-30
WO2005058892A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE442367T1 (de) Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
NO20053600L (no) Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer.
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
GEP20084552B (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
NO952178L (no) Katekol-dietere som selektive PDEIV inhibitekorer
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
EA200700219A1 (ru) ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 МАР КИНАЗЫ
EA200970158A1 (ru) Производные хинуклидина в качестве антагонистов м3
ATE540948T1 (de) Pyrrolopyridine als proteinkinasehemmer
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
WO2008096870A1 (ja) アザ架橋環化合物
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
CY1111625T1 (el) Ενωσεις πυραζολο[3,4-β]πυριδινης και χρηση αυτων ως αναστολεις pde4
RU2005115504A (ru) Соединения 7-фенилпиразолопиридина
NO20092413L (no) Pyrazolanaloger
DE60203106D1 (de) Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen
WO2010074409A3 (ko) Ccr2 길항제로서의 3-아미노피롤리딘 유도체
MY135776A (en) PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
NO20064805L (no) Sammensetninger for behandling av sykdommer
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer
TH88614A (th) สารประกอบใหม่

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application